Effects of low-molecular-weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers

Blood Coagulation and Fibrinolysis

Volumn 7, Issue 1, 1996, Pages 49-56

  Harenberg, J ^a   Jeschek, M ^a   Acker, M ^a   Malsch, R ^a   Huhle, G ^a   Heene, D L ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Coagulation; Fibrinolysis; LMW dermatan sulfate; Protamine chloride; Tissue factor pathway inhibitor

Indexed keywords

DERMATAN SULFATE; DESMIN; PROTAMINE CHLORIDE; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029980290     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199601000-00006     Document Type: Article

References (35)

1. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 803-813.
2. Sandset PM, Hogevold HE, Lybert T, Andersson TR, Abildgaard U. Extrinsic pathway inhibitor in elective surgery: a comparison with other coagulation inhibitors. Thromb Haemostas 1989; 62: 856-860.
3. Lindahl AK, Abildgaard U, Staalesen R. The anticoagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor. Thromb Res 1991; 64: 155-168.
4. Harenberg J, Schäfer M, Stehle G, Schmidt M, Dempfle CE, Heene DL. Release of the extrinsic pathway inhibitor, hepatic lipase and anti-factor Xa activity into post-heparin plasma. Thromb Haemostas 1991; 65: 915.
5. Valentin S, Ostergaard P, Kristensen H, Nordfang O. Simultaneous presence of tissue factor pathway inhibitor (TFPI) and low molecular weight heparin has a synergistic effect in different coagulation assays. Blood Coag Fibrinol 1991; 2: 629-635.
6. Lindahl AK, Sandset PM, Abildgaard U. The present status of tissue factor pathway inhibitor. Blood Coag Fibrinol 1992; 3: 439-449.
7. Harenberg J, Stehle G, Dempfle CE, Heene DL. Release of tissue factor pathway inhibitor by different glycosaminoglycans - evidence of a specific heparin binding site. Ann Hematol 1993; 66 (suppl 1): 159.
8. Harenberg J, Siegele M, Dempfle CE, Stehle G, Heene DL. Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins. Thromb Haemostas 1993; 70: 942-943.
9. Zitoun D, Bara L, Bloch MF, Samama MM. Plasma TFPI activity after intravenous injection of pentasaccharide (PS) and unfractionated heparin in rabbits. Thromb Res 1994; 75: 577-580.
10. Lindahl AK, Sandset PM, Abildgaard U. The present status of tissue factor pathway inhibitor. Blood Coag Fibrinol 1992; 3: 439-449.
11. Radziwon P, Keppler S, Glusa E, Markwardt F, Breddin KH. Effects of multiple s.c. doses of a new low molecular weight heparin (SSH) on coagulation and platelet function in healthy volunteers. Ann Hematol 1995, 70 (suppl I): 19 (A).
12. Dettori AG, Galli G, Manotti C, Palazzini E. Pharmacological activity of a low molecular weight dermatan sulphate (Desmin) in healthy volunteers. Semin Thromb Hemost 1994; 20: 259-265.
13. Legnani C, Palareti G, Biagi R, et al. Acute and chronic clotting and fibrinolytic effect of a new low molecular weight dermatan sulphate (Desmin 370) in healthy subjects. Eur J Clin Pharm (accepted).
14. Mascellani G, Bianchini P. European Patent 1990, No. 0221977. USA Patent 1990, No. 4973580.
15. Ofosu FA, Modi GJ, Smith LM. Cerskus AL, Hirsh J, Blajchman M. Heparansulphate and dermatan sulphate inhibit the generation of thrombin activity in plasma by complementary pathways. Blood 1984, 64: 742-747.
16. Tollefsen DM, Petska CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulphate. J Biol Chem 1983, 258: 6713-6717.
17. Abbadini M, Jin Zhu G, Maggi A, Pangrazzi J, Donati MB, Mussoni L. Dermatan sulfate plasminogen activator release in the perfused rat hindquarters. Blood 1987; 70: 1858-1860.
18. Maggi A, Abbadini A, Pagella PG, Borowska A, Pangrazzi J, Donati MB. Antithrombotic properties of dermatan sulphate in a rat venous thrombosis model. Haemostasis 1987: 17: 329-355.
19. Fernandez F, Van Ryn J, Ofosu FA, Hirsh J, Buchanan MR. The hemorrhagic and antithrombotic effects of dermatan sulphate. Br J Haematol 1986; 64: 309-327.
20. Iqbal O, Hoppenstaed D, Walenga JM, Kindel J, Strano A, Fareed J. Molecular weight dependence of the anti-protease and anticoagulant actions of depolymerized dermatan sulphate preparations. Thromb Haemostas 1993; 69: 1319 (abstract).
21. Merton RE, Thomas DP. Experimental studies on the relative efficacy of dermatan sulphate and heparin as antithrombotic agents. Thromb Haemostas 1987; 58: 839-842.
22. Sie P, Ofosu FA, Fernandez F, Buchanan MR, Petitou M, Boneu B. Respective role of antithrombin III and heparin cofactor II in the in vitro anticoagulant effect of various sulphated polysaccharides. Br J Haematol 1986; 64: 707-714.
23. Dawes J, Hodson BA, MacGregor IR, Pepper DS, Prowse CV. Pharmaco-kinetics and biological activities of dermatan sulphate (Mediolanum MF 701) in healthy human volunteers. Ann NY Acad Sci 1989; 556: 292-303.
24. Dawes J, McLaren M, Forbes C, et al. The pharmacokinetics of dermatan sulphate MF701 in healthy volunteers. Br J Clin Pharmacol 1991; 32: 361-366.
25. Dawes J. The pharmacokinetics of LMW dermatan sulphate: long-term persistence of intact material. Thromb Haemostas 1993; 69: 339-343.
26. Dol F, Houin G, Rostin M, et al. Pharmacodynamics and pharmacokinetics of dermatan sulfate in humans. Blood 1989; 74: 1577-1582.
27. Dol F, Petitou M, Lormeau JC, et al. Pharmacologic properties of a low molecular weight dermatan sulphate: comparison with unfractionated dermatan sulphate. J Lab Clin Med 1990; 115: 43-51.
28. Harenberg J, de Vries JX. Characterization of heparins by high performance size exclusion liquid chromatography. J Chromatogr 1983; 261: 287-292.
29. Sandset PM, Abildgaard U, Pettersen M. A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions. Thromb Res 1987; 47: 389-400.
30. Harenberg J, Giese Ch, Knödler A, Zimmermann R. Comparative study on a new one-stage clotting assay for heparin and its low molecular weight derivatives. Haemoitasis, 1989; 19: 13-20.
31. Harenberg J. Modified anti-factor Xa chromogenic substrate assay for heparin and low molecular weight heparins. Ärztl Lab 1987; 33: 39-41.
32. Harenberg J. Pharmacology of low molecular weight heparins. Semin Thromb Hemost 1990; 16: 12-18.
33. Thomas DP, Merton RE. A low-molecular-weight heparin compared with unfractionated heparin. Thromb Res 1982; 28: 343-351.
34. Harenberg J, Gnasso A, de Vries JX, Zimmermann R, Augustin J. Inhibition of low molecular weight heparin by protamine chloride in vivo. Thromb Res 1985; 38: 11-20.
35. Harenberg J, Stehle G, Augustin J, Zimmermann R. Comparative human pharmacology of low molecular weight heparins. Semin Thromb Hemost 1989; 15: 414-423.